Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway

Journal of Molecular and Cellular Cardiology

Volumn 88, Issue , 2015, Pages 29-38

  Zhao, Claire Y ^a   Greenstein, Joseph L ^a   Winslow, Raimond L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac myocytes; Computational model; Cyclic nucleotides; Phosphodiesterase; Signaling networks; adrenergic pathway

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; SPLEEN EXONUCLEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; PDE2A PROTEIN, HUMAN; PDE3A PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HYDROLYSIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; BINDING COMPETITION; BINDING SITE; BIOLOGICAL MODEL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CYTOLOGY; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; HEART CONTRACTION; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HUMANS; MICE; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84942520519     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.09.011     Document Type: Article

References (91)

1. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75:725-748.
2. Conti M., Mika D., Richter W. Cyclic AMP compartments and signaling specificity: role of cyclic nucleotide phosphodiesterases. J. Gen. Physiol. 2014, 143:29-38.
3. Francis S.H., Blount M.A., Corbin J.D. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 2011, 91:651-690.
4. Miller C.L., Yan C. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J. Cardiovasc. Transl. Res. 2010, 3:507-515.
5. Zaccolo M., Movsesian M.A. cAMP and cGMP signaling cross-talk role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 2007, 100:1569-1578.
6. Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100:309-327.
7. Ding B., Abe J.-I., Wei H., Xu H., Che W., Aizawa T., et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14771-14776.
8. Lehnart S.E., Wehrens X.H., Reiken S., Warrier S., Belevych A.E., Harvey R.D., et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005, 123:25-35.
9. Molina C.E., Leroy J., Richter W., Xie M., Scheitrum C., Lee I.-O., et al. Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. J. Coll. Cardiol. 2012, 59:2182-2190.
10. Ding B., Abe J.-I., Wei H., Huang Q., Walsh R.A., Molina C.A., et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005, 111:2469-2476.
11. Abi-Gerges A., Richter W., Lefebvre F., Mateo P., Varin A., Heymes C., et al. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on β-adrenergic cAMP signals. Circ. Res. 2009, 105:784-792.
12. Mehel H., Emons J., Vettel C., Wittköpper K., Seppelt D., Dewenter M., et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J. Coll. Cardiol. 2013, 62:1596-1606.
13. Marín-García J. Cyclic Nucleotides Signaling (Second Messengers) and Control of Myocardial Function: Effects of Heart Failure 2010, 161-169. Heart Failure: Humana Press.
14. Knight W., Yan C. Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. Horm. Metab. Res. 2012, 44:766. (Hormon-und Stoffwechselforschung=Hormones et metabolisme).
15. Yan C., Ding B., Shishido T., Woo C.-H., Itoh S., Jeon K.-I., et al. Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ. Res. 2007, 100:510-519.
16. Kostic M., Erdogan S., Rena G., Borchert G., Hoch B., Bartel S., et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J. Mol. Cell. Cardiol. 1997, 29:3135-3146.
17. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109:366-398.
18. Conti M., Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76:481-511.
19. Fischmeister R., Castro L.R., Abi-Gerges A., Rochais F., Jurevičius J., Leroy J., et al. Compartmentation of cyclic nucleotide signaling in the heart the role of cyclic nucleotide phosphodiesterases. Circ. Res. 2006, 99:816-828.
20. Beavo J.A., Brunton L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3:710-718.
21. Maurice D.H., Ke H., Ahmad F., Wang Y., Chung J., Manganiello V.C. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 2014, 13:290-314.
22. Antos L.L.K., Schmidt H.H., Hoffmann F., Stasch J.-P. cGMP: Generators, Effectors and Therapeutic Implications 2009, Springer.
23. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 2002, 1:309-315.
24. Graves J.D., Krebs E.G. Protein phosphorylation and signal transduction. Pharmacol. Ther. 1999, 82:111-121.
25. Saucerman J.J., McCulloch A.D. Cardiac β-adrenergic signaling. Ann. Acad. Sci. 2006, 1080:348-361.
26. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
27. Francis S.H., Corbin J.D., Bischoff E. Cyclic GMP-Hydrolyzing Phosphodiesterases. cGMP: Generators, Effectors and Therapeutic Implications 2009, 367-408. Springer.
28. Kass D.A., Takimoto E., Nagayama T., Champion H.C. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 2007, 75:303-314.
29. Zhang M., Koitabashi N., Nagayama T., Rambaran R., Feng N., Takimoto E., et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell. Signal. 2008, 20:2231-2236.
30. Zoraghi R., Corbin J.D., Francis S.H. Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol. Pharmacol. 2004, 65:267-278.
31. Saucerman J.J., Brunton L.L., Michailova A.P., McCulloch A.D. Modeling β-adrenergic control of cardiac myocyte contractility in silico. J. Biol. Chem. 2003, 278:47997-48003.
32. Iancu R.V., Jones S.W., Harvey R.D. Compartmentation of cAMP signaling in cardiac myocytes: a computational study. Biophys. J. 2007, 92:3317-3331.
33. Kraeutler M., Soltis A., Saucerman J. Modeling cardiac β-adrenergic signaling with normalized-hill differential equations: comparison with a biochemical model. BMC Syst. Biol. 2010, 4:157.
34. 2+ in β-adrenergic signaling, accelerating β-adrenergic inotropy. J. Mol. Cell. Cardiol. 2012, 52:1048-1055.
35. 2+-transient. J. Mol. Cell. Cardiol. 2011, 50:863-871.
36. Saucerman J.J., Healy S.N., Belik M.E., Puglisi J.L., McCulloch A.D. Proarrhythmic consequences of a KCNQ1 AKAP-binding domain mutation: computational models of whole cells and heterogeneous tissue. Circ. Res. 2004, 95:1216-1224.
37. Massion P.B., Balligand J.L. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J. Phys. 2003, 546:63-75.
38. Keef K.D., Hume J.R., Zhong J. Regulation of Cardiac and Smooth Muscle Ca2+Channels (CaV1.2a,b) by Protein Kinases 2001.
39. 2+current facilitation: a modeling study. Biophys. J. 2009, 96:1770-1785.
40. Segel I.H. Enzyme Kinetics 1975, Wiley, New York.
41. Martinez S.E., Wu A.Y., Glavas N.A., Tang X.-B., Turley S., Hol W.G.J., et al. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc. Natl. Acad. Sci. 2002, 99:13260-13265.
42. Castro L.R.V., Verde I., Cooper D.M.F., Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006, 113:2221-2228.
43. Herget S., Lohse M.J., Nikolaev V.O. Real-time monitoring of phosphodiesterase inhibition in intact cells. Cell. Signal. 2008, 20:1423-1431.
44. Nikolaev V.O., Gambaryan S., Engelhardt S., Walter U., Lohse M.J. Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J. Biol. Chem. 2005, 280:1716-1719.
45. Rochais F., Abi-Gerges A., Horner K., Lefebvre F., Cooper D.M., Conti M., et al. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ. Res. 2006, 98:1081-1088.
46. + current in rat ventricular myocytes. \J. Pharmacol. 1999, 127:65-74.
47. Yan C., Zhao A.Z., Bentley J.K., Beavo J.A. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem. 1996, 271:25699-25706.
48. Prigent A., Fougier S., Nemoz G., Anker G., Pacheco H., Lugnier C., et al. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta: separation and inhibition by selective reference phosphodiesterase inhibitors. Biochem. Pharmacol. 1988, 37:3671-3681.
49. Beavo J., Hardman J.G., Sutherland E.W. Stimulation of adenosine 3', 5'-monophosphate hydrolysis by guanosine 3', 5'-monophosphate. J. Biol. Chem. 1971, 246:3841-3846.
50. Komas N., Le Bec A., Stoclet J.-C., Lugnier C. Cardiac cGMP-stimulated cyclic nucleotide phosphodiesterases: effects of cGMP analogues and drugs. Eur. J. Pharmacol. Mol. Pharmacol. 1991, 206:5-13.
51. Yamamoto T., Yamamoto S., Osborne J., Manganiello V., Vaughan M., Hidaka H. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J. Biol. Chem. 1983, 258:14173-14177.
52. Martins T.J., Mumby M., Beavo J. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J. Biol. Chem. 1982, 257:1973-1979.
53. Whalin M.E., Strada S.J., Thompson W. Purification and partial characterization of membrane-associated type II (cGMP-activatable) cyclic nucleotide phosphodiesterase from rabbit brain. Biochimica et biophysica acta (BBA)-molecular. Cell Res. 1988, 972:79-94.
54. Osadchii O.E. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc. Drugs Ther. 2007, 21:171-194.
55. Francis S.H., Busch J.L., Corbin J.D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62:525-563.
56. He R., Komas N., Ekholm D., Murata T., Taira M., Hockman S., et al. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3). Cell Biochem. Biophys. 1998, 29:89-111.
57. Vila Petroff M.G., Egan J.M., Wang X., Sollott S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res. 2001, 89:445-452.
58. Kuznetsov V., Pak E., Robinson R.B., Steinberg S.F. β2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes. Circ. Res. 1995, 76:40-52.
59. Zaccolo M., Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002, 295:1711-1715.
60. Götz K.R., Sprenger J.U., Perera R.K., Steinbrecher J.H., Lehnart S.E., Kuhn M., et al. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes. Circ. Res. 2014, 114:1235-1245.
61. Mongillo M., Tocchetti C.G., Terrin A., Lissandron V., Cheung Y.-F., Dostmann W.R., et al. Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ. Res. 2006, 98:226-234.
62. Mongillo M., McSorley T., Evellin S., Sood A., Lissandron V., Terrin A., et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res. 2004, 95:67-75.
63. Johnson W., Katugampola S., Able S., Napier C., Harding S. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. Life Sci. 2012, 90:328-336.
64. Méry P.F., Pavoine C., Pecker F., Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol. Pharmacol. 1995, 48:121-130.
65. Boess F.G., Hendrix M., van der Staay F.-J., Erb C., Schreiber R., van Staveren W., et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47:1081-1092.
66. Hambleton R., Krall J., Tikishvili E., Honeggar M., Ahmad F., Manganiello V.C., et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J. Biol. Chem. 2005, 280:39168-39174.
67. + current, activated by β1- and β2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. J. Pharmacol. 2009, 156:62-83.
68. Bethke T., Meyer W., Schmitz W., Scholz H., Stein B., Thomas K., et al. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. J. Pharmacol. 1992, 107:127-133.
69. Torphy T.J., Undem B. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991, 46:512-523.
70. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009, 202:419-443.
71. Boswell-Smith V., Spina D., Page C.P. Phosphodiesterase inhibitors. J. Pharmacol. 2006, 147:S252-S257.
72. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 2005, 11:214-222.
73. Houslay M.D., Schafer P., Zhang K.Y.J. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 2005, 10:1503-1519.
74. Yan C., Miller C.L. Abe J-i. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ. Res. 2007, 100:489-501.
75. Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 2006, 5:660-670.
76. Rahnama'i M.S., Ückert S., Hohnen R., van Koeveringe G.A. The role of phosphodiesterases in bladder pathophysiology. Nat. Rev. Urol. 2013, 10:414-424.
77. Richter W., Xie M., Scheitrum C., Krall J., Movsesian M.A., Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res. Cardiol. 2011, 106:249-262.
78. Lehnart S.E., Marks A.R. Phosphodiesterase 4D and heart failure: a cautionary tale. Expert Opin. Ther. Targets 2006, 10:677-688.
79. Terasaki W., Appleman M. The role of cyclic GMP in the regulation of cyclic AMP hydrolysis. Metabolism 1975, 24:311-319.
80. Bode D.C., Kanter J.R., Brunton L.L. Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ. Res. 1991, 68:1070-1079.
81. Perera R.K., Sprenger J.U., Steinbrecher J.H., Hübscher D., Lehnart S.E., Abesser M., et al. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy. Circ. Res. 2015, 116:1304-1311.
82. Saucerman J.J., Greenwald E.C., Polanowska-Grabowska R. Mechanisms of cyclic AMP compartmentation revealed by computational models. J. Gen. Physiol. 2014, 143:39-48.
83. Perera R.K., Nikolaev V.O. Compartmentation of cAMP signalling in cardiomyocytes in health and disease. Acta Physiol. 2013.
84. Edwards H.V., Christian F., Baillie G.S. cAMP: Novel Concepts in Compartmentalised Signalling. Seminars in cell & developmental biology 2012, 181-190. Elsevier.
85. Kritzer M.D., Li J., Dodge-Kafka K., Kapiloff M.S. AKAPs: the architectural underpinnings of local cAMP signaling. J. Mol. Cell. Cardiol. 2012, 52:351-358.
86. Mika D., Leroy J., Vandecasteele G., Fischmeister R. PDEs create local domains of cAMP signaling. J. Mol. Cell. Cardiol. 2012, 52:323-329.
87. Ahmad F., Shen W., Vandeput F., Szabo-Fresnais N., Krall J., Degerman E., et al. Regulation of SERCA2 activity by PDE3A in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J. Biol. Chem. 2015, M115:638585. jbc.
88. Katz A. Physiology of the Heart 2011, Wolters Kluwer Health.
89. Tsai E.J., Kass D.A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 2009, 122:216-238.
90. Senzaki H., Smith C.J., Juang G.J., Isoda T., Mayer S.P., Ohler A., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001, 15:1718-1726.
91. Lu Z., Xu X., Hu X., Lee S., Traverse J.H., Zhu G., et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010, 121:1474-1483.